Claims:

1. A depot system, particularly for delayed release of active substances, characterized in that said system comprises liposomes with
   - saturated synthetic phosphatidyl cholines selected from the group of DMPC, DPPC and/or DSPC,
   - cholesterol with a percentage of from 35 to 50 mole-%,
   - cationic lipids selected from the group of DC-Chol, DAC-Chol, DMTAP, DPTAP and/or DOTAP with a percentage of from 5 to 20 mole-% in the liposomal membrane, and
   - at least one protein and/or peptide active substance.

2. The depot system according to claim 1, characterized in that the cationic lipids are cationic in a pH-sensitive fashion and selected from the group of His-Chol and/or Mo-Chol.

3. The depot system according to any of the preceding claims, characterized in that at least 90% of the active substance is enclosed in the liposome and less than 10% is outside the liposome.

4. The depot system according to any of the preceding claims, characterized in that the active substance is entrapped in the liposome and more than 10% thereof is outside the liposome.

5. The depot system for delayed release of active substances according to any of the preceding claims, characterized in that delivery of the active substance is sustained for at least 1 week.

6. The depot system according to any of the preceding claims, characterized in that the size of the liposomes varies from 20 to 1,000 nm, particularly from 50 to 800 nm, and preferably from 50 to 300 nm.

7. Use of the depot system according to any of claims 1 to 6 for subcutaneous or intramuscular application.

8. Use of the depot system according to any of claims 1 to 6 for a depot of LHRH agonists and/or GnRH analogs, said depot system comprising, in particular, leuprolide acetate, buserelin, goserelin and/or triptorelin.

9. Use of a depot system according to claim 1, 2 or 3 for a depot for insulin, said peptide active substance comprising a therapeutically useful insulin.

10. The use according to any of the preceding claims for a depot of heparin, said active substance comprising heparin.

11. The use according to any of the preceding claims for a depot of antigen fragments for vaccination.

12. The use according to any of the preceding claims for delayed release of active substances for at least one week, said depot system comprising oligonucleotides.

13. The use according to the preceding claim, characterized in that

the oligonucleotides are constituted of 5-100, preferably of 5-40, and more preferably 10-25 deoxyribonucleotides, ribonucleotides or chemically modified derivatives thereof.

14. The use according to the preceding claim, characterized in that the oligonucleotides are present as a single strand, particularly as antisense oligonucleotides, as a double strand, particularly as small interfering RNA, decoy oligonucleotides and/or in complex folding, particularly as aptamers, spiegelmers.

15. Use of the depot system according to any of claims 1 to 6 in the production of a drug.

16. Use of the depot system according to any of the preceding claims for topical and local application, especially to support healing processes.

17. Use of the depot system according to any of claims 1 to 6 for delayed release of an active substance for at least one week, said active substance comprising a water-soluble active substance derivative selected from the classes of active substances of antibiotic, antimycotic, cytostatic agents or glucocorticoids.

18. A kit comprising at least one depot system according to any of claims 1 to 6, optionally together with information of combining the contents of the kit.